The Ketone Body β-Hydroxybutyrate Does Not Inhibit Synuclein Mediated Inflammasome Activation in Microglia

Abstract

Parkinson's disease (PD) is recognized as the most common neurodegenerative movement disorder and results in debilitating motor deficits. The accumulation and spread of neurotoxic synuclein aggregates in the form of Lewy bodies is a key pathological feature of PD. Chronic activation of the NLRP3 inflammasome by protein aggregates is emerging as a major pathogenic mechanism in progressive neurodegenerative disorders and is considered an important therapeutic target. Recently the ketone body, β-hydroxy butyrate (BHB), was shown to efficiently inhibit the NLRP3 inflammasome in macrophages, and in vivo models of inflammatory disease. Furthermore, BHB can readily cross the blood brain barrier suggesting that it could have therapeutic benefits for the management of PD. In this study, we evaluated if BHB could inhibit chronic microglial inflammasome activation induced by pathological fibrillar synuclein aggregates. Interestingly, we found that BHB treatment almost completely blocked all aspects of inflammasome activation and pyroptosis induced by ATP and monosodium urate (MSU) crystals, consistent with previously published reports in macrophages. Surprisingly however, BHB did not inhibit inflammasome activation and release of IL-1β or caspase-1 induced by synuclein fibrils. Our results demonstrate that BHB does not block the upstream pathways regulating inflammasome activation by synuclein fibrils and suggest that synuclein mediated inflammasome activation proceeds via distinct mechanisms compared to traditional NLRP3 activators such as ATP and MSU.

The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins

“…Cells were then incubated in a humidified CO 2 incubator at 37 C. The media was changed after 4-5 days and the mixed glial cells were allowed to grow to the desired confluence. Separation of microglial cells were performed at 14-16 days with a column-free magnetic separation system as described in previous reports (Deora, Albornoz, Zhu, Woodruff, & Gordon, 2017;Gordon et al, 2011).…”

β-Hydroxybutyrate Oxidation Promotes the Accumulation of Immunometabolites in Activated Microglia Cells

“…The role of BHB in microglia and neuroinflammation has been previously studied in various disease models [ 26 , 36 , 38 , 53 , 54 , 55 , 56 , 57 ]. However, the metabolic effects of BHB on microglia activation and the underlying metabolic reprogramming remain unknown.…”

Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review

“…[139][140][141] β-Hydroxybutyrate (BHB) is a ketone body that is produced as an adaptive starvation response during a negative energy balance. 142 BHB inhibits the NLRP3 inflammasome in macrophages and neutrophils. 143,144 Although IL-1β or IL-1 receptor antagonists have been approved by the FDA and have been shown to be effective in some clinical trials, the high costs and potential risk may limit their use.…”